These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 10537366)

  • 21. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
    Kikuchi T; Miyazawa N; Moore MA; Crystal RG
    Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene.
    Murakami T; Tokunaga N; Waku T; Gomi S; Kagawa S; Tanaka N; Fujiwara T
    Clin Cancer Res; 2004 Jun; 10(11):3871-80. PubMed ID: 15173096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo.
    Soh EY; Eigelberger MS; Kim KJ; Wong MG; Young DM; Clark OH; Duh QY
    Surgery; 2000 Dec; 128(6):1059-65;discussion 1065-6. PubMed ID: 11114643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
    Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
    Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The effect of antibody against vascular endothelial growth factor on tumor growth].
    Wang G; Wang N; Liu T
    Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):163-6. PubMed ID: 10920886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.
    Gerber HP; Kowalski J; Sherman D; Eberhard DA; Ferrara N
    Cancer Res; 2000 Nov; 60(22):6253-8. PubMed ID: 11103779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG; Kim TD; Li G; Yoon WH; Chae CB
    Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
    Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
    Viloria-Petit A; Crombet T; Jothy S; Hicklin D; Bohlen P; Schlaeppi JM; Rak J; Kerbel RS
    Cancer Res; 2001 Jul; 61(13):5090-101. PubMed ID: 11431346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors.
    Luo JC; Yamaguchi S; Shinkai A; Shitara K; Shibuya M
    Cancer Res; 1998 Jun; 58(12):2652-60. PubMed ID: 9635593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production.
    Fusetti L; Pruneri G; Gobbi A; Rabascio C; Carboni N; Peccatori F; Martinelli G; Bertolini F
    Cancer Res; 2000 May; 60(9):2527-34. PubMed ID: 10811135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.
    Tatsumi T; Takehara T; Kanto T; Miyagi T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N
    Cancer Res; 2001 Oct; 61(20):7563-7. PubMed ID: 11606395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
    Pan JP; Weng YS; Wu QQ
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors.
    Nagaraj S; Pisarev V; Kinarsky L; Sherman S; Muro-Cacho C; Altieri DC; Gabrilovich DI
    J Immunother; 2007; 30(2):169-79. PubMed ID: 17471164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced antimetastatic effect of fetal liver kinase 1 extracellular domain and interferon-gamma fusion gene-modified dendritic cell vaccination.
    Pan J; Heiser A; Marget M; Steinmann J; Kabelitz D
    Gene Ther; 2005 May; 12(9):742-50. PubMed ID: 15729371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immunotherapy against tumor with dendritic cell sensitized by necrotic tumor tissue after microwave coagulation therapy].
    Yao LC; Yang RJ
    Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(36):2552-6. PubMed ID: 18067832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy.
    Kirk CJ; Hartigan-O'Connor D; Nickoloff BJ; Chamberlain JS; Giedlin M; Aukerman L; Mule JJ
    Cancer Res; 2001 Mar; 61(5):2062-70. PubMed ID: 11280767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.